HPLC (High Performance Liquid Chromatography) method for rapidly and simultaneously separating and determining rifamycin SV, rifamycin S and rifamycin B in fermentation liquor
By optimizing chromatographic conditions using high-performance liquid chromatography (HPLC), the problem of separating and determining rifamycin B, SV, and S in the fermentation broth of *Amylopectinus thaliana* was solved, achieving rapid and accurate detection results and supporting research on the biosynthetic pathway of rifamycin and its yield improvement.
Patent Information
- Application Number
- CN202411234279.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-04
- Publication Date
- 2024-11-26
AI Technical Summary
The lack of a rapid and simultaneous method for separating and determining rifamycin B, rifamycin SV, and rifamycin S in the fermentation broth of Acidobacterium mediterranei has hindered the exploration of the rifamycin biosynthetic pathway and the improvement of its yield.
A high-performance liquid chromatography (HPLC) method was established to simultaneously separate and determine rifamycin B, rifamycin SV, and rifamycin S by selecting appropriate chromatographic columns and gradient elution modes and optimizing chromatographic conditions. The method includes standard curve establishment, sample pretreatment, and detection steps.
This method enables rapid and accurate separation and quantification of rifamycin SV, rifamycin S, and rifamycin B in fermentation broth, simplifying the operation and improving detection efficiency and accuracy.
Smart Images

Figure CN119023845A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of biopharmaceutical detection, and in particular to an HPLC method for rapidly and simultaneously separating and determining rifamycin SV, rifamycin S and rifamycin B in fermentation broth. Background Art
[0002] Rifamycin is an ansamycin antibiotic with antimycobacterial activity, which is widely used in the treatment of tuberculosis, leprosy and mycobacterial infections related to AIDS. It was first discovered by the Italian Lepetit Company in 1957 from the culture of Amycolatopsis Nocardia. In 1959, Sensi et al. first isolated rifamycin S from the fermentation broth of Amycolatopsis Mediterranei. Due to different producing bacterial species, there are many types of rifamycins in the fermentation broth, including rifamycin A, B, C, D, E, S and SV. Among them, rifamycin B, S and SV are more important and can be converted into each other.
[0003] There are a variety of rifamycin components in the fermentation broth of A. mediterranei. Rifamycin SV is the precursor of the biosynthesis of rifamycin B, and the rifamycin B component is oxidized, hydrolyzed and reduced to obtain rifamycin SV. Rifamycin SV can be spontaneously chemically oxidized to rifamycin S by oxygen under aerobic conditions.
[0004] By consulting the literature and patents, it is found that there are currently few methods for separating and determining multiple rifamycin components in A. mediterranei fermentation broth, and most of the methods only focus on the detection of a single component. No method has been reported that can quickly and simultaneously determine the contents of rifamycin B, rifamycin SV and rifamycin S in A. mediterranei fermentation broth. This situation is not conducive to exploring the metabolic pathways of rifamycin-producing bacteria, determining the key metabolic targets for regulating rifamycin biosynthesis, and increasing the production of rifamycin antibiotics. Therefore, an effective analytical method that can simultaneously and quickly separate and determine the contents of rifamycin B, rifamycin SV and rifamycin S in fermentation broth is urgently needed. Summary of the invention
[0005] In order to solve the above technical problems, the present invention provides an HPLC method for simultaneously and rapidly separating rifamycin B, S, SV and related substances in A. mediterranei fermentation broth. According to the properties of rifamycin SV, rifamycin S and rifamycin B, the present invention selects a chromatographic column with good retention, optimizes the chromatographic conditions, and finally establishes an HPLC method for simultaneously detecting rifamycin SV, rifamycin S and rifamycin B in A. mediterranei fermentation broth in a gradient elution manner, providing another option for sensitive, rapid and accurate determination of rifamycin and its related substances.
[0006] The specific technical scheme of the present invention is:
[0007] The present invention provides an HPLC method for simultaneously separating and determining rifamycin SV, rifamycin S and rifamycin B and related substances in A. mediterranei fermentation broth. In the method, the structural formulas of the rifamycin SV, rifamycin S and rifamycin B are:
[0008]
[0009] The HPLC assay method comprises the following steps:
[0010] S1. Standard curve establishment
[0011] Weigh rifamycin SV, rifamycin S and rifamycin B standards accurately, dissolve and dilute them into standard working solutions. Analyze by HPLC to obtain chromatograms of each sample, and establish a standard curve with the peak area of the analyte as the ordinate and the concentration of the analyte as the abscissa.
[0012] S2. Pre-treatment of samples to be tested
[0013] Accurately measure the fermentation liquid to be tested, extract and dilute it, and then centrifuge it to obtain the supernatant;
[0014] S3. Testing of samples to be tested
[0015] HPLC was used for analysis to obtain the chromatogram of each sample, and the concentrations of rifamycin SV, rifamycin S and rifamycin B in the sample fermentation broth were calculated using the standard curve.
[0016] The preparation method of the standard working solutions of fufamycin SV, rifamycin S and rifamycin B in step S1 is as follows: accurately weigh three rifamycins, dissolve them in acetonitrile to prepare a high concentration standard stock solution, and then dilute them in acetonitrile to prepare a series of standard working solutions. The standard stock solutions are stored in a -20°C refrigerator.
[0017] The concentrations of the standard working solutions of the series of concentrations are divided into 6 concentration points (SA-SE), as follows:
[0018]
[0019] In step S2, the fermentation medium components are: 100 g / L glucose, 10 g / L soybean cake powder, 10 g / L peptone, 5 g / L fish meal, 8 g / L potassium nitrate, 5 g / L calcium carbonate, 0.2 g / L potassium dihydrogen phosphate, and 1 g / L cobalt chloride hexahydrate.
[0020] Preferably, the reagent used to dissolve and dilute the standard in step S1 is acetonitrile.
[0021] In step S2, the fermentation broth of the sample to be tested is A. mediterranei fermentation broth (such as fermentation broth of A. mediterranei U32), and the reagents used for its pretreatment are acetonitrile and water, acetonitrile / water (v / v) = 1:1, preferably acetonitrile.
[0022] Preferably, the method for pre-treatment of the fermentation broth of the sample to be tested in step S2 is: accurately weigh an appropriate amount of fermentation broth, add 9 times the volume of acetonitrile, vortex for 1 to 1.5 minutes, stand for extraction for 5 minutes, centrifuge, and take out the supernatant, which is the sample to be tested, for HPLC injection analysis.
[0023] Preferably, the vortex oscillation time is 1 to 1.5, and the static extraction time is 5 minutes.
[0024] Preferably, the centrifugation is at 3000 rpm, the centrifugation temperature is room temperature, and the centrifugation is for 10 min.
[0025] In step S1 or S3, the HPLC chromatographic mobile phase is set as follows: mobile phase A is a buffer solution; mobile phase B is an organic solvent, and gradient elution is performed according to the following table:
[0026] Time (minutes) Mobile phase A (%) Mobile phase B (%) 0 60 40 1 60 40 3 37 63 6 37 63 6.1 25 75 9 25 75 9.1 5 95 15 5 95 15.1 60 40 16 60 40
[0027] More preferably, the gradient elution conditions are:
[0028] Time (minutes) Mobile phase A (%) Mobile phase B (%) 0 60 40 1 60 40 3 37 63 6 37 63 6.1 25 75 9 25 75 9.1 5 95 13.5 5 95 13.6 60 40 14.5 60 40
[0029] The experiment found that only under the setting conditions of the chromatographic mobile phase can a better separation and detection effect be achieved.
[0030] Preferably, the HPLC chromatographic conditions in step S1 or S3 further include:
[0031] Detector: UV detector;
[0032] Flow rate: 1 mL / min;
[0033] Column temperature: 40°C;
[0034] Injection volume: 5 μL;
[0035] Detection wavelength: 254nm;
[0036] Run time: 14.5 minutes
[0037] Preferably, the chromatographic column of the HPLC analysis method in step S1 or S3 is ZORBAX Eclipse XDB-C18, with a length of 150 mm, an inner diameter of 4.6 mm, and a particle size of 5 μm.
[0038] The mobile phase A, the buffer solution is ammonium formate solution, disodium hydrogen phosphate solution, preferably ammonium formate solution, and its concentration is 10-50mmol / L, preferably 50mmol / L.
[0039] The mobile phase B, the organic solvent is an acetonitrile-methanol mixed solution, the ratio of which is 1:1-2, preferably 1:2.
[0040] The aqueous solutions used in the present invention are all ultrapure water, and the organic reagents used are all HPLC grade.
[0041] The significant advantages of the present invention are:
[0042] (1) The present invention proposes a method for simultaneously and rapidly separating and determining rifamycin SV, rifamycin S and rifamycin B and their related substances in A. mediterranei fermentation broth. By using high performance liquid chromatography, effective separation and quantification of rifamycin SV, rifamycin S and rifamycin B in the fermentation broth can be achieved, and at the same time, effective separation of other related impurities can be achieved.
[0043] (2) The present invention reasonably optimizes the pretreatment of the fermentation broth sample, thereby providing an efficient and stable pretreatment method for the fermentation broth sample, which has a short processing time and is simple to operate.
[0044] (3) The detection technology provided by the present invention has good separation, short analysis time and high accuracy, and can better achieve the purpose of accurate quantification of rifamycin SV, rifamycin S and rifamycin B in the fermentation broth. BRIEF DESCRIPTION OF THE DRAWINGS
[0045] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art are briefly introduced below.
[0046] Figure 1 The chromatogram of the mixed standard solution of rifamycin SV, rifamycin S and rifamycin B detected by method ① in Example 1;
[0047] Figure 2The chromatogram of the mixed standard solution of rifamycin SV, rifamycin S and rifamycin B detected by method ② in Example 1;
[0048] Figure 3 The chromatogram of the mixed standard solution of rifamycin SV, rifamycin S and rifamycin B detected by method ③ in Example 1;
[0049] Figure 4 The chromatogram of the fermentation broth sample detected by method ③ in Example 1;
[0050] Figure 5 The chromatogram of the mixed standard solution of rifamycin SV, rifamycin S and rifamycin B detected by method ④ in Example 1;
[0051] Figure 6 The chromatogram of the fermentation broth sample detected by method ④ in Example 1;
[0052] Figure 7 The chromatogram of the mixed standard solution of rifamycin SV, rifamycin S and rifamycin B detected by method ⑤ in Example 1;
[0053] Figure 8 The chromatogram of the fermentation broth sample detected by method ⑤ in Example 1;
[0054] Fig. 9 The standard curve for determining rifamycin SV in fermentation broth established by the present invention in Example 3;
[0055] Fig.10 The standard curve for determining rifamycin S in fermentation broth established by the present invention in Example 3;
[0056] Fig.11 The standard curve for determining rifamycin B in fermentation broth established by the present invention in Example 3;
[0057] Fig.12 The chromatogram of a blank sample (specifically acetonitrile) measured by the HPLC method established by the present invention;
[0058] Fig.13 This is the chromatogram of the rifamycin SV standard determined by the HPLC method established by the present invention;.
[0059] Fig.14 The chromatogram of the rifamycin S standard product determined by the HPLC method established by the present invention;
[0060] Fig.15 The chromatogram of the rifamycin B standard product determined by the HPLC method established by the present invention;
[0061] Fig.16The chromatogram of the fermentation broth sample determined by the HPLC method established by the present invention;
[0062] Fig.17 for Fig.16 Chromatographic peak results table. DETAILED DESCRIPTION
[0063] The present invention is further described below in conjunction with specific examples, but the protection scope of the present invention is not limited thereto. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.
[0064] Unless otherwise specified, all reagents and materials used in the present invention are commercially available.
[0065] The HPLC mentioned in the article is the abbreviation of high performance liquid chromatography technology.
[0066] Instrument and chromatographic conditions:
[0067] Instrument: Agilent 1260 Infinity II HPLC;
[0068] Detector: UV detector;
[0069] Flow rate: 1 mL / min;
[0070] Column temperature: 40°C;
[0071] Injection volume: 5 μL;
[0072] Detection wavelength: 254nm;
[0073] Example 1: Selection and optimization of chromatographic columns and chromatographic conditions
[0074] Prepare rifamycin SV, rifamycin S and rifamycin B standard products and their mixed standard solutions:
[0075] Reagent ①: Accurately weigh 0.0118 g of rifamycin SV standard (1 mg is equivalent to 847 rifamycin units) into a 10 mL brown volumetric flask, dissolve and dilute to volume with acetonitrile, shake well to obtain a rifamycin SV standard solution with a concentration of 1000 μg / mL.
[0076] Reagent ②: Accurately weigh 0.0105 g of rifamycin S standard (HPLC grade 94.8%) into a 10 mL brown volumetric flask, dissolve and dilute to volume with acetonitrile, shake well to obtain a rifamycin S standard solution with a concentration of 1000 μg / mL.
[0077] Reagent ③: Accurately weigh 0.0107 g of rifamycin B standard (HPLC grade 92.9%) into a 10 mL brown volumetric flask, dissolve and dilute to volume with acetonitrile, shake well to obtain a rifamycin S standard solution with a concentration of 1000 μg / mL.
[0078] The samples were filtered through 0.22 μm organic filter membrane into injection bottles for HPLC detection.
[0079] Add 2 mL of reagent ①, 2 mL of reagent ② and 2 mL of reagent ③ to a 10 mL brown volumetric flask, dilute with acetonitrile and make up to volume to obtain a mixed standard solution containing 200 μg / mL of rifamycin SV, rifamycin S and rifamycin B, filter with a 0.22 μm organic filter membrane into an injection bottle for HPLC detection.
[0080] The source of the fermentation broth sample and the pretreatment method used were the same as those in Example 2 (shake flask fermentation broth sample of Amycolatopsis mediterranei U32 fermentation culture for 168 h, pretreatment method 2).
[0081] Based on the above instruments and chromatographic conditions, continue to screen the most suitable chromatographic conditions.
[0082] ①Chromatographic column 1: Unitary C18 (4.6mm×250mm, 5um)
[0083] Mobile phase: Mobile phase A is 25mmol / L disodium hydrogen phosphate solution (pH adjusted to 6.9±0.1 with phosphoric acid); mobile phase B is acetonitrile / methanol = 1:1; elution is performed according to elution gradient 1 in Table 1:
[0084] Table 1 Elution gradient 1
[0085] Time (minutes) Mobile phase A (%) Mobile phase B (%) 0 60 40 1 60 40 3 37 63 6 37 63 6.1 25 75 9 25 75 9.1 5 95 15 5 95 15.1 60 40 16 60 40
[0086] Method ① was used to detect the standard solutions of rifamycin SV, rifamycin S and rifamycin B and the mixed standard solution of the three, and the chromatograms were recorded.
[0087] Results: Example 1: Method ① was used to detect the mixed standard solution of rifamycin SV, rifamycin S and rifamycin B to obtain the spectrum as shown in Figure 1 shown.
[0088] By using the external standard method, it has been confirmed that the retention time of 4.361min is rifamycin B, and the retention time of 12.789 is rifamycin SV. No rifamycin S was detected in the obtained spectrum, and there was an asymmetric peak shape of rifamycin B, indicating that the chromatographic column has no retention effect on rifamycin S, so it is necessary to replace the chromatographic column and adjust the chromatographic conditions.
[0089] ② Column 2: ZORBAX Eclipse XDB-C18 (4.6mm×150mm, 5um)
[0090] Mobile phase: Mobile phase A was 25 mmol / L disodium hydrogen phosphate solution (pH adjusted to 6.9±0.1 with phosphoric acid); mobile phase B was acetonitrile / methanol = 1:1.
[0091] The other conditions are the same as ①.
[0092] Method ② was used to detect the standard solutions of rifamycin SV, rifamycin S and rifamycin B and their mixed standard solutions, and the chromatograms were recorded.
[0093] Results: Example 1: Method ② was used to detect the mixed standard solution of rifamycin SV, rifamycin S and rifamycin B to obtain the spectrum as shown in Figure 2 shown.
[0094] The retention time of the rifamycin B peak was 4.575 min, the retention time of the rifamycin SV peak was 7.067 min, and the retention time of the rifamycin S peak was 7.454 min. Among them, there was a tailing problem at the front of the chromatographic peak of rifamycin B, and the chromatographic peaks of rifamycin SV and rifamycin S, resulting in asymmetric peak shapes. In order to improve the peak shapes of the chromatographic peaks of rifamycin SV, rifamycin S and rifamycin B, the chromatographic conditions were further adjusted, and the mobile phase A was changed to 50 mmol / L ammonium formate solution.
[0095] ③Chromatographic column 2: ZORBAX Eclipse XDB-C18 (4.6 mm × 150 mm, 5 um);
[0096] Mobile phase A was 50 mmol / L ammonium formate solution, and mobile phase B was acetonitrile / methanol (v / v) = 1:1.
[0097] The other conditions are the same as ①.
[0098] Method ③ was used to detect rifamycin SV, rifamycin S, rifamycin B standard solutions, mixed standard solutions of the three and fermentation broth samples, and the chromatograms were recorded.
[0099] Results: Example 1: Method ③ was used to detect the mixed standard solution of rifamycin SV, rifamycin S and rifamycin B to obtain the spectrum as shown in Figure 3 As shown, the fermentation liquid sample spectrum was detected by method ③. Figure 4 shown.
[0100] By replacing the 25mmol / L disodium hydrogen phosphate solution (pH adjusted to 6.9±0.1 with phosphoric acid) with a 50mmol / L ammonium formate solution, the front and tail problems of the chromatographic peaks were solved, and the peak shapes of the three mixed standard solutions were effectively separated with good peak symmetry. However, due to the large number of impurities in the fermentation broth, when this method was used to detect the fermentation broth, rifamycin B could not be separated from its adjacent impurities, and the separation degree was low ( Figure 4 ). Further optimization is needed to consider increasing the methanol content in mobile phase B to improve the resolution.
[0101] ④Chromatographic column 2: ZORBAX Eclipse XDB-C18 (4.6 mm × 150 mm, 5 um);
[0102] Mobile phase A was 50 mmol / L ammonium formate solution, and mobile phase B was acetonitrile / methanol (v / v) = 1:2.
[0103] The other conditions are the same as ①.
[0104] Method ④ was used to detect rifamycin SV, rifamycin S, rifamycin B standard solutions, mixed standard solutions of the three and fermentation broth samples, and the chromatograms were recorded.
[0105] Results: Example 1: Method ④ was used to detect the mixed standard solution of rifamycin SV, rifamycin S and rifamycin B to obtain the spectrum as shown in Figure 5 As shown, the fermentation liquid sample spectrum is detected by method ④ as shown in Figure 6 shown.
[0106] The peak shapes of the mixed standard solutions of rifamycin SV, rifamycin S and rifamycin B were effectively separated and had good peak symmetry. Figure 5 The separation degree between rifamycin B and the nearest impurity peak in the fermentation broth is good, the peak shapes of rifamycin SV and rifamycin S are symmetrical, the other impurity peaks are well separated, and the peak shapes of each impurity peak are good. Figure 6 However, the detection time is relatively long, at 16 minutes, and the elution time needs to be further adjusted.
[0107] ⑤ Column 2: ZORBAX Eclipse XDB-C18 (4.6mm×150mm, 5um)
[0108] Mobile phase A was 50 mmol / L ammonium formate solution, mobile phase B was acetonitrile / methanol (v / v) = 1:2, running time was 14.5 min, eluted according to elution gradient 2 in Table 2:
[0109] Table 2 Elution gradient 2
[0110] Time (minutes) Mobile phase A (%) Mobile phase B (%) 0 60 40 1 60 40 3 37 63 6 37 63 6.1 25 75 9 25 75 9.1 5 95 13.5 5 95 13.6 60 40 14.5 60 40
[0111] The other conditions are the same as ①.
[0112] Method ⑤ was used to detect rifamycin SV, rifamycin S, rifamycin B standard solutions, mixed standard solutions of the three and fermentation broth samples, and the chromatograms were recorded.
[0113] Results: Example 1: Method ⑤ was used to detect the mixed standard solution of rifamycin SV, rifamycin S and rifamycin B to obtain the spectrum as shown in Figure 7 As shown, the fermentation liquid sample spectrum is detected by method ⑤ as shown in Figure 8 shown.
[0114] By adjusting the elution time, the elution time was shortened from 16 min to 14.5 min. Figure 7 and Figure 8 It can be seen that the peak shapes of the mixed standard solutions of rifamycin SV, rifamycin S and rifamycin B are effectively separated, and the peak shapes are symmetrical. The three main components in the fermentation broth are effectively separated, among which the separation between rifamycin B and the nearest adjacent impurity peak is good, and the separation between other effective impurity peaks is greater than 2.0. The peak shapes of each impurity peak are good, and the detection speed is fast, which meets the detection requirements of actual production.
[0115] Example 2: Comparative test of different pre-treatment methods for fermentation broth
[0116] Prepare fermentation medium: 100 g / L glucose, 10 g / L soybean meal, 10 g / L peptone, 5 g / L fish meal, 8 g / L potassium nitrate, 5 g / L calcium carbonate, 0.2 g / L potassium dihydrogen phosphate, 1 g / L cobalt chloride hexahydrate, sterilize with high pressure steam, 121°C, 30 min. Amycolatopsis mediterranei U32 was used for rifamycin SV fermentation expression, and fermentation culture was carried out in a 250 mL triangular flask. The shake flask fermentation broth sample after 168 h of fermentation culture was taken as the fermentation broth sample to be tested.
[0117] Fermentation broth pretreatment method 1: Take 0.5 mL of the fermentation broth sample to be tested in a centrifuge tube, add 9 times the volume of purified water, vortex and shake for 1 to 1.5 minutes, let it stand for extraction for 5 minutes, centrifuge at 3000 rpm for 10 minutes, take the supernatant, and microfilter it with a 0.22 μm water filter membrane into a sample injection bottle for HPLC injection analysis.
[0118] Fermentation broth pretreatment method 2: Take 0.5 mL of the fermentation broth sample to be tested in a centrifuge tube, add 9 times the volume of acetonitrile, vortex and shake for 1 to 1.5 minutes, let it stand for extraction for 5 minutes, centrifuge at 3000 rpm for 10 minutes, take the supernatant, and microfilter it with a 0.22 μm organic filter membrane into a sample injection bottle for HPLC injection analysis.
[0119] Fermentation broth pretreatment method 3: Take 0.5 mL of the fermentation broth sample to be tested in a centrifuge tube, add 9 volumes of acetonitrile / water (v / v) = 1:1 solution, vortex for 1-1.5 min, let stand for extraction for 5 min, centrifuge at 3000 rpm for 10 min, take the supernatant, and microfilter it with a 0.22 μm organic filter membrane into a sample injection bottle for HPLC injection analysis.
[0120] The fermentation broth samples treated differently were subjected to HPLC analysis using method ⑤ in Example 1.
[0121] result:
[0122] After the fermentation broth was treated with fermentation broth pretreatment method 1, rifamycin SV was unstable and would be continuously converted into rifamycin S as the standing time increased, and the measured result was low, so the contents of rifamycin SV and rifamycin S in the fermentation broth could not be accurately determined; after the fermentation broth was treated with fermentation broth pretreatment method 2, the situation improved slightly, but some rifamycin SV would still be converted into rifamycin S, so the fermentation broth treated with this method was still unstable; when pure acetonitrile (fermentation broth pretreatment method 2) was used to extract and dilute the fermentation broth, the conversion of rifamycin SV to rifamycin S could be effectively inhibited, the stability of the fermentation broth could be improved, and the contents of rifamycin SV, rifamycin S and rifamycin B in the fermentation broth could be accurately determined.
[0123] In summary, the fermentation broth pretreatment method 2 in Example 2 is the fermentation broth pretreatment method of the present invention, and the method ⑤ in Example 1 is the HPLC detection method of the present invention. The contents of rifamycin SV, rifamycin S and rifamycin B in the fermentation broth are determined in production practice. Specifically:
[0124] Fermentation broth pretreatment method: take 0.5 mL of fermentation broth into a centrifuge tube, add 9 times the volume of acetonitrile, vortex and shake for 1 to 1.5 minutes, let it stand for extraction for 5 minutes, centrifuge at 3000 rpm for 10 minutes, take the supernatant, microfilter it with a 0.22 μm organic filter membrane into a sample injection bottle for HPLC injection analysis.
[0125] HPLC detection method:
[0126] Mobile phase A was 50 mmol / L ammonium formate solution, mobile phase B was acetonitrile / methanol (v / v) = 1:2, gradient elution was adopted, and the specific elution gradient was shown in elution gradient 2;
[0127] Detector: UV detector;
[0128] Flow rate: 1 mL / min;
[0129] Column temperature: 40°C;
[0130] Injection volume: 5 μL;
[0131] Detection wavelength: 254nm;
[0132] Running time: 14.5min;
[0133] Chromatographic column: ZORBAX Eclipse XDB-C18 (4.6mm×150mm, 5um).
[0134] Example 3: The method of the present invention is used to simultaneously detect rifamycin SV, rifamycin S and rifamycin B in the fermentation broth, and a standard curve is drawn to perform quantitative analysis using the external standard method.
[0135] 1) Draw a standard curve
[0136] Test reagents:
[0137] Reagent ①: Accurately weigh 0.0118 g of rifamycin SV standard (1 mg is equivalent to 847 rifamycin units) into a 10 mL brown volumetric flask, dissolve and dilute to volume with acetonitrile, shake well to obtain a rifamycin SV standard solution with a concentration of 1000 μg / mL.
[0138] Reagent ②: Accurately weigh 0.0105 g of rifamycin S standard (HPLC grade 94.8%) into a 10 mL brown volumetric flask, dissolve and dilute to volume with acetonitrile, shake well to obtain a rifamycin S standard solution with a concentration of 1000 μg / mL.
[0139] Reagent ③: Accurately weigh 0.0107 g of rifamycin B standard (HPLC grade 92.9%) into a 10 mL brown volumetric flask, dissolve and dilute to volume with acetonitrile, shake well to obtain a rifamycin S standard solution with a concentration of 1000 μg / mL.
[0140] Test plan:
[0141] Separate standard curves of rifamycin SV, rifamycin S and rifamycin B were drawn: reagent ① was diluted with acetonitrile at 10, 50, 100, 200, 400 and 800 μg / mL to obtain gradient solutions with 6 concentration points (SA-SF).
[0142] Then, the sample was injected and measured according to method ⑤ in Example 1: mobile phase A was 50 mmol / L ammonium formate solution, mobile phase B was acetonitrile / methanol (v / v) = 1:2, and gradient elution was adopted. The specific elution gradient is shown in Table 2 Elution Gradient 2;
[0143] Detector: UV detector;
[0144] Flow rate: 1 mL / min;
[0145] Column temperature: 40°C;
[0146] Injection volume: 5 μL;
[0147] Detection wavelength: 254nm;
[0148] Running time: 14.5min;
[0149] Chromatographic column: ZORBAX Eclipse XDB-C18 (4.6mm×150mm, 5um).
[0150] Finally, draw the standard curve; perform the same operation on reagents ② and ③, and finally draw the standard curve, see Table 3, Table 4, Table 5 and Fig. 9 , Fig.10 , Fig.11 .
[0151] Table 3 Rifamycin SV standard curve detection results
[0152] Concentration (μg / mL) Peak area (mAU·s) Peak time (min) 10 116.824 7.898 50 544.639 7.893 100 1210.321 7.870 200 2429.704 7.844 400 4869.966 7.803 800 9740.319 7.740
[0153] Table 4 Rifamycin S standard curve detection results
[0154] Concentration (μg / mL) Peak area (mAU·s) Peak time (min) 10 83.656 10.902 50 396.402 10.903 100 818.692 10.903 200 1699.822 10.908 400 3457.050 10.913 800 6969.809 10.928
[0155] Table 5 Rifamycin B standard curve detection results
[0156]
[0157]
[0158] Fig. 9 is the standard curve of rifamycin SV, Fig.10 is the standard curve of Rifamycin S, Fig.11 is the standard curve of rifamycin B.
[0159] The results of this embodiment show that, through the determination of rifamycin SV, rifamycin S and rifamycin B standard solutions, it is concluded that the method of the present invention has a good linear relationship (R2=0.99996) for rifamycin SV between 10-800 mg / L, a good linear relationship (R2=0.99993) for rifamycin S between 10-800 mg / L, and a good linear relationship (R2=0.99995) for rifamycin B between 10-800 mg / L, as shown in Table 6.
[0160] Pretreatment of the fermentation broth of the sample to be tested: The fermentation broth sample was treated according to the fermentation broth pretreatment method 2 in Example 2. 0.5 mL of the fermentation broth was taken into a centrifuge tube, 9 volumes of acetonitrile were added, vortexed for 1 to 1.5 min, allowed to stand for extraction for 5 min, centrifuged at 3000 rpm for 10 min, the supernatant was taken, and microfiltered with a 0.22 μm organic filter membrane into a sample injection bottle to obtain a test solution.
[0161] S3. Testing of samples to be tested
[0162] The test solution was subjected to HPLC analysis according to method ⑤ in Example 1 to obtain the corresponding peak areas, and the concentrations of rifamycin SV, rifamycin S and rifamycin B in the test solution were obtained based on the standard curve.
[0163] The chromatogram of one of the test solutions is as follows: Fig.16 As shown, Fig.17 for Fig.16 Peak result table.
[0164] The contents of rifamycin SV, rifamycin S and rifamycin B in the fermentation broth were calculated according to formula (1):
[0165]
[0166] Where:
[0167] x: the content of rifamycin SV, rifamycin S and rifamycin B in the fermentation broth, in milligrams per liter (mg / L);
[0168] c: The concentrations of rifamycin SV, rifamycin S and rifamycin B in the test solution were obtained from the standard curve in milligrams per liter (mg / L);
[0169] v1: fermentation broth volume;
[0170] v2: The volume of acetonitrile added to the fermentation broth.
[0171] In the method of the present invention, in the standard solution, the average retention times of rifamycin SV, rifamycin S and rifamycin B are 7.841min, 10.909min and 5.350min respectively. The specific data of the linear range, linear equation, correlation coefficient and quantitative limit of rifamycin SV, rifamycin S and rifamycin B are shown in Table 6 below:
[0172] Table 6 Linear range, linear equation, correlation coefficient, detection limit, and quantification limit of rifamycin SV, rifamycin S, and rifamycin B
[0173] Compound Linear range Linear equations <![CDATA[Coefficient of correlation R 2 > Detection limit Limit of Quantitation Rifamycin SV 10-800mg / L y=12.2014x-17.4790 0.99996 0.08mg / L 0.2mg / L Rifamycin S 10-800mg / L y=8.7321x-28.0887 0.99993 0.10mg / L 0.3mg / L Rifamycin B 10-800mg / L y=6.9654x-1.9078 0.99995 0.12mg / L 0.4mg / L
[0174] In the experiment, the sample without the target substance was used as the matrix, spiked at the concentration of the instrument detection limit, and the signal-to-noise ratio was determined. The qualitative detection limit of the method was determined by 3 times the signal-to-noise ratio (S / N), among which rifamycin SV was 0.08 mg / L, rifamycin S was 0.1 mg / L; rifamycin B was 0.12 mg / L, and the quantitative limit of the method was determined by 10 times the signal-to-noise ratio, among which rifamycin SV was 0.2 mg / L, rifamycin S was 0.3 mg / L, and rifamycin B was 0.4 mg / L.
[0175] Prepare shake flask fermentation broth sample: 100 g / L glucose, 10 g / L soybean meal, 10 g / L peptone, 5 g / L fish meal, 8 g / L potassium nitrate, 5 g / L calcium carbonate, 0.2 g / L potassium dihydrogen phosphate, 1 g / L cobalt chloride hexahydrate, sterilize with high pressure steam, 121°C, 30 min. Amycolatopsis mediterranei U32 was used for rifamycin SV fermentation expression, and fermentation culture was carried out in a 250 mL triangular flask. The shake flask fermentation broth sample after fermentation culture for 168 hours was taken as the fermentation broth sample to be tested, and the fermentation broth sample was treated according to the fermentation broth pretreatment method 2 in Example 2.
[0176] Using the above detection method, samples of fermentation broth from 5 different shake flasks were injected and tested to determine the contents of rifamycin SV, rifamycin S and rifamycin B in the fermentation broth. The specific data are shown in Table 7:
[0177] Table 7 Detection results of rifamycin SV, rifamycin S and rifamycin B in different shake flask fermentation broth samples
[0178] Sample No. 1 2 3 4 5 Rifamycin SV content (mg / L) 2050 2653 2675 1876 2597 Rifamycin S (mg / L) 985 457 332 1765 362 Rifamycin B (mg / L) 600 547 543 376 432
[0179] The results showed that among the five test sample solutions, rifamycin SV, rifamycin S and rifamycin B had good separation, the minimum separation between rifamycin SV and adjacent impurities was 2.88, the minimum separation between rifamycin S and adjacent impurities was 5.78, and the minimum separation between rifamycin B and adjacent impurities was 2.02, all of which were greater than 1.5. The peak shape was sharp and good, the peak purity was good, the theoretical plate numbers were 17257 for rifamycin SV, 37054 for rifamycin S, and 26541 for rifamycin B, all of which were greater than 3000, and the tailing factors were 1.04 for rifamycin SV, 1.02 for rifamycin S, and 1.01 for rifamycin B, all of which met the standards, see Fig.16 / 17.
[0180] Example 4: Recovery determination
[0181] The recovery rate of this method was determined by adding low, medium and high concentration standards of rifamycin SV, rifamycin S and rifamycin B into the fermentation broth for standard sample addition and recovery.
[0182] 1) Reagent preparation method:
[0183] Reagent ①: Accurately weigh 0.02163 g of rifamycin SV standard (1 mg is equivalent to 847 rifamycin units) into a 10 mL brown volumetric flask, dissolve and dilute to volume with acetonitrile, shake well to obtain a rifamycin SV standard solution with a concentration of 1800 μg / mL.
[0184] Reagent ②: Accurately weigh 0.0190 g of rifamycin S standard (HPLC grade 94.8%) into a 10 mL brown volumetric flask, dissolve and dilute to volume with acetonitrile, shake well to obtain a rifamycin S standard solution with a concentration of 1800 μg / mL.
[0185] Reagent ③: Accurately weigh 0.0194 g of rifamycin B standard (HPLC grade 92.9%) into a 10 mL brown volumetric flask, dissolve and dilute to volume with acetonitrile, shake well to obtain a rifamycin B standard solution with a concentration of 1800 μg / mL.
[0186] Reagent ④: Mix the above reagents ①, ② and ③ together, mix well, and obtain a standard solution containing 600 μg of rifamycin SV, rifamycin S and rifamycin B per ml, and set aside;
[0187] Reagent ⑤: Take 0.5 mL of the fermentation broth to be tested in Example 2 (shake flask fermentation broth sample of Amycolatopsis mediterranei U32 fermented for 168 h) in a centrifuge tube, add 9 volumes of acetonitrile, vortex for 1-1.5 min, let stand for extraction for 5 min, centrifuge at 3000 rpm for 10 min, remove the supernatant and set aside;
[0188] 2) Recovery test of low concentration rifamycin SV, rifamycin S and rifamycin B:
[0189] Take 950μL of reagent ⑤ and 50μL of reagent ④ in a 1.5mL centrifuge tube, shake and mix, and then use a 0.22μm organic filter membrane to filter into a sample injection bottle for detection. Control sample: Replace reagent ④ in this method with 50μL acetonitrile, and follow the same steps for three times to calculate the recovery rate. The results are shown in the following table.
[0190] Table 8 Low concentration recoveries and relative standard deviations of rifamycin SV, rifamycin S and rifamycin B
[0191]
[0192] 3) Recovery test of medium concentration rifamycin SV, rifamycin S and rifamycin B:
[0193] Take 400μL of reagent ⑤ and 600μL of reagent ④ in a 1.5mL centrifuge tube, shake and mix, and then use a 0.22μm organic filter membrane to filter into a sample injection bottle for detection. Control sample: Replace reagent ④ in this method with 600μL acetonitrile, and follow the same steps for three times to calculate the recovery rate. The results are shown in the following table.
[0194] Table 9 Concentration recovery and relative standard deviation of rifamycin SV, rifamycin S and rifamycin B
[0195]
[0196] 4) Recovery test of high concentration rifamycin SV, rifamycin S and rifamycin B:
[0197] Take 50μL of reagent ⑤ and 950μL of reagent ④ in a 1.5mL centrifuge tube, shake and mix, and then use a 0.22μm organic filter membrane to filter into a sample injection bottle for detection. Control sample: Replace reagent ④ in this method with 950μL acetonitrile, and the rest of the steps are the same. Perform the operation three times and calculate the recovery rate. The results are shown in the following table.
[0198] Table 10 High concentration recovery and relative standard deviation of rifamycin SV, rifamycin S and rifamycin B
[0199]
[0200] As shown in Table 8 / 9 / 10, in 9 recovery tests, the average recovery rate of rifamycin SV was 98.63%, RSD=1.01 (n=9); the average recovery rate of rifamycin S was 97.09%, RSD=1.02 (n=9), and the average recovery rate of rifamycin B was 100.16%, RSD=0.95 (n=9). Therefore, the recovery rate of this method is very good and suitable for production needs.
[0201] In summary, the present invention provides a HPLC method for rapid and simultaneous separation and determination of the contents of rifamycin SV, rifamycin S and rifamycin B in fermentation broth, which is suitable for the detection and analysis of the contents of rifamycin SV, rifamycin S and rifamycin B in fermentation broth. The method is fast (14.5 min / needle), highly accurate, highly precise, simple to operate, has high-throughput sample detection capability, can effectively monitor the changes in the contents of the three substances during the fermentation process, and can meet the timely monitoring in production.
[0202] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. A HPLC method for rapid and simultaneous separation and determination of rifamycin SV, rifamycin S and rifamycin B in fermentation broth, Features The method comprises the following steps: S1. Standard curve establishment: Accurately weigh rifamycin SV, rifamycin S and rifamycin B standards, dissolve and dilute them into standard working solutions, analyze them by HPLC, obtain chromatograms of each sample, and establish a standard curve with the peak area of the analyte as the ordinate and the concentration of the analyte as the abscissa; S2. Pre-treatment of the fermentation liquid of the sample to be tested: Accurately measure the fermentation liquid to be tested, extract and dilute it, and then centrifuge it to obtain the supernatant; S3. Testing of samples to be tested: HPLC was used for analysis to obtain the chromatogram of each sample, and the concentrations of rifamycin SV, rifamycin S and rifamycin B in the sample fermentation broth were calculated using the standard curve.
2. The method according to claim 1, Features: The reagent used for dissolving, diluting and extracting in step S1 or S3 is acetonitrile.
3. The method according to claim 1, Features: The fermentation broth pretreatment method in step S2 is: accurately weigh an appropriate amount of fermentation broth, add 9 times the volume of acetonitrile, vortex and shake for 1 to 1.5 minutes, let it stand for 5 minutes, centrifuge at 3000 rpm for 10 minutes, and take out the supernatant, which is the test solution, for HPLC injection analysis.
4. The method according to claim 1, It is characterized in that The chromatographic conditions and program settings are: Detector: UV detector; Flow rate: 1 mL / min; Column temperature: 40°C; Injection volume: 5 μL; Detection wavelength: 254nm; Running time: 14.5min; Chromatographic column: ZORBAX Eclipse XDB-C18, length 150 mm, inner diameter 4.6 mm, particle size 5 μm.
5. The method according to claim 1, It is characterized in that In step S1 or S3, the chromatographic mobile phase of HPLC is set as follows: mobile phase A is 50mmol / L ammonium formate solution, mobile phase B is acetonitrile / methanol (v / v) = 1:2, all samples are separated by gradient elution mode, the running time is 14.50min, and the optimized gradient elution conditions are 0-1min: 40%B; 1-3min: 63%B; 3-6min: 63%B; 6-6.1 min: 75%B; 6.1-9 min: 75%B; 9-9.1:95%B; 9.1-13.5min: 95%B; 13.5-13.6min: 40%B.
